Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

MLA

Osterborg, Anders, et al. Ofatumumab Retreatment and Maintenance in Fludarabine-Refractory Chronic Lymphocytic Leukaemia Patients. 2015. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1234103027&authtype=sso&custid=ns315887.

APA

Osterborg, A., Wierda, W. G., Mayer, J., Hess, G., Hillmen, P., Schetelig, J., Schuh, A., Smolej, L., Beck, C., Dreyfus, B., Hellman, A., Kozlowski, P., Pfreundschuh, M., Rizzi, R., Spacek, M., Phillips, J. L., Gupta, I. V., Williams, V., Jewell, R. C., … Dyer, M. J. S. (2015). Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.

Chicago

Osterborg, Anders, William G. Wierda, Jiri Mayer, Georg Hess, Peter Hillmen, Johannes Schetelig, Anna Schuh, et al. 2015. “Ofatumumab Retreatment and Maintenance in Fludarabine-Refractory Chronic Lymphocytic Leukaemia Patients.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1234103027&authtype=sso&custid=ns315887.